Neuropro Therapeutics
Yachats, US · North Carolina corporation
NeuroPro is developing NPT 2042, a drug candidate targeting epilepsy, with reported efficacy in pharmacology models comparable to NKCC antagonists such as bumetanide and furosemide. The compound has shown plasma exposure across species including humans and no negative safety signals in animals or humans to date.
Founders & leadership
DW
Daryl W. HochmanFounder
Board
LS
Louis SerafiniBoard director
LC
Luciano CacioppoBoard director
Reported raises · per SEC filings
Form D private placements$5.3M disclosed across 2 rounds · 2016–2023
▶$5.1MraisedApr 2023 · 2 investors · BiotechnologyRule 506(b)
▶$5.1MraisedApr 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daryl W. HochmanExecutive Officer, Director
- Louis SerafiniDirector
- Luciano CacioppoDirector
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- First sale
- Mar 2023
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$215.9KraisedDec 2016 · 4 investors · BiotechnologyRule 506(b)
▶$215.9KraisedDec 2016 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- DARYL HOCHMANExecutive Officer, Director
- Offering amount
- $220K
- Amount sold
- $215.9K
- First sale
- Jul 2016
- Incorporated
- Corporation, North Carolina, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Insitro4 shared keywordsinsitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines. The company serves patients and pharmaceutical development by integrating in vitro lab data with human clinical data to decode biology and unlock transformative treatments.
Monopar Therapeutics4 shared keywordsMonopar Therapeutics is a clinical-stage biotechnology company developing radiopharmaceuticals for oncology imaging and treatment of advanced solid tumors, along with ALXN1840, a late-stage investigational treatment for Wilson Disease, a rare genetic disorder. It advances its pipeline through in-house development and licensing of late-preclinical and clinical-stage therapeutics.
Companies competing with Neuropro Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Neuropro Therapeutics do?
- NeuroPro is developing NPT 2042, a drug candidate targeting epilepsy, with reported efficacy in pharmacology models comparable to NKCC antagonists such as bumetanide and furosemide. The compound has shown plasma exposure across species including humans and no negative safety signals in animals or humans to date.
- Who founded Neuropro Therapeutics?
- Neuropro Therapeutics was founded by Daryl W. Hochman.
- How much funding has Neuropro Therapeutics raised?
- Neuropro Therapeutics has disclosed $5.3M raised across 2 rounds.
- Where is Neuropro Therapeutics headquartered?
- Neuropro Therapeutics is headquartered in Yachats, US.